Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
| Autor: | Nur Atika, Cicih Opitasari, Thanaporn Bussabawalai, Septiara Putri, Yot Teerawattananon, Oktavia Lilyasari, Lucia Kris Dinarti, Anggita Bunga Anggraini, Yusuf Subekti |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Budgets
medicine.medical_specialty Sildenafil Cost-Benefit Analysis Hypertension Pulmonary Vasodilator Agents Beraprost Pulmonary arterial hypertension Sildenafil Citrate 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Value for money Societal perspective medicine Humans 030212 general & internal medicine business.industry lcsh:Public aspects of medicine 030503 health policy & services Health Policy lcsh:RA1-1270 PAH Budget impact Epoprostenol Economic evaluation chemistry Indonesia Emergency medicine 0305 other medical science business Research Article medicine.drug |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 19, Iss 1, Pp 1-9 (2019) |
| ISSN: | 1472-6963 |
| DOI: | 10.1186/s12913-019-4422-5 |
| Popis: | Background This study aims to assess the cost-effectiveness and budget impact of adopting sildenafil to the benefits package for the indication of pulmonary arterial hypertension (PAH), compared to beraprost. Methods Based on a societal perspective, a model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs). Results The economic model calculated the incremental cost-effectiveness ratio (ICER) per QALY gained for using sildenafil as first-line therapy compared to beraprost for the patient in functional class (FC) II and III, i.e. USD 3098 and USD 2827, respectively. The results indicated that in spite of sildenafil being more expensive than beraprost, generic sildenafil could potentially be a good value for money since ICER per QALY is below one times gross domestic product (GDP) per capita in Indonesia. Furthermore, budget impact analysis estimated that the incremental budget needed within 5 years for including sildenafil compared to beraprost for PAH patients starting in FC II and FC III was USD 436,775 and USD 3.6 million, respectively. Conclusions Compared to beraprost, sildenafil would be preferable for the treatment of PAH patients in FC II and FC III in Indonesia. The additional budget for adopting sildenafil compared to beraprost as the treatment of PAH in the benefits package was estimated at around USD 4.0 million. Electronic supplementary material The online version of this article (10.1186/s12913-019-4422-5) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink